This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Technische Universität München. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations of Daniel Di Carlo in Radiopharmaceuticals
Introduction
Daniel Di Carlo is an accomplished inventor based in Haimhausen, Germany. He has made significant contributions to the field of radiopharmaceuticals, particularly through his innovative work on silicon-fluoride acceptor substituted compounds. His research focuses on developing new ligands that can effectively target specific proteins, which is crucial for advancements in medical imaging and treatment.
Latest Patents
One of Daniel Di Carlo's notable patents is titled "Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof." This patent describes a ligand-SiFA conjugate compound represented by a specific formula. The compound includes a ligand moiety capable of binding to prostate-specific membrane antigen (PSMA) and a silicon-fluoride acceptor (SiFA) moiety that can be labeled with fluorine. The design also incorporates a hydrophilic moiety made up of a sequence of hydrophilic amino acid units, enhancing the compound's effectiveness in medical applications. This patent showcases his innovative approach to improving radiopharmaceuticals.
Career Highlights
Daniel Di Carlo is affiliated with the Technische Universität München, where he continues to engage in groundbreaking research. His work has not only contributed to the academic community but has also paved the way for practical applications in the medical field. His dedication to advancing radiopharmaceutical technology is evident in his research and patent contributions.
Collaborations
Throughout his career, Daniel has collaborated with esteemed colleagues, including Hans-Jürgen Wester and Hans-Jurgen Wester. These collaborations have further enriched his research and have led to significant advancements in the field of radiopharmaceuticals.
Conclusion
Daniel Di Carlo's innovative work in the field of radiopharmaceuticals exemplifies the impact of targeted research on medical technology. His contributions, particularly through his patent on silicon-fluoride acceptor compounds, highlight the importance of innovation in improving healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile